









Markets
/
Stocks
/
nasdaq-nbix
/

Neurocrine Biosciences Inc

NBIX

145.480USD

+2.750+1.93%

Market hours （ET）Quotes delayed by 15 min

14.40BMarket Cap

41.35P/E TTM



Neurocrine Biosciences Inc

145.480

+2.750+1.93%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

2 / 175

Overall Ranking

40 / 4723

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 28 analysts

Buy

Current Rating

165.796

Target Price

+17.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 58.21% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 120.91.

Fairly Valued

The company’s latest PE is 41.01, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 98.30M shares, decreasing 5.51% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 9.77M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 8.64, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 687.50M, representing a year-over-year increase of 16.49%, while its net profit experienced a year-over-year increase of 65.38%.

Score

Industry at a Glance

Previous score

8.64

Change



Financials

7.41

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.14

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.66

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 4.81, which is higher than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 41.01, which is 44.04% below the recent high of 59.06 and 8.04% above the recent low of 37.71.

Score

Industry at a Glance

Previous score

4.84

Change

-0.03

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 2/175

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.36, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Neurocrine Biosciences Inc is 166.50, with a high of 200.00 and a low of 124.00.

Score

Industry at a Glance

Previous score

8.36

Change

Support & Resistance

No Data

Analyst Rating

Based on 28 analysts

Buy

Current Rating

165.796

Target Price

+16.16%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Neurocrine Biosciences Inc

NBIX

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 9.04, which is higher than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 148.38 and the support level at 134.50, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.81

Change

0.23

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.313

Neutral

RSI(14)

59.601

Neutral

STOCH(KDJ)(9,3,3)

60.846

Neutral

ATR(14)

3.610

High Vlolatility

CCI(14)

53.543

Neutral

Williams %R

30.059

Buy

TRIX(12,20)

0.339

Sell

StochRSI(14)

55.445

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

141.908

Buy

MA10

142.326

Buy

MA20

139.637

Buy

MA50

134.691

Buy

MA100

128.124

Buy

MA200

125.583

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 99.11%, representing a quarter-over-quarter decrease of 1.59%. The largest institutional shareholder is The Vanguard, holding a total of 9.77M shares, representing 9.85% of shares outstanding, with 1.08% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

10.78M

-1.63%

The Vanguard Group, Inc.

Star Investors

9.90M

-2.26%

Dodge & Cox

Star Investors

5.53M

+83.48%

State Street Global Advisors (US)

4.86M

-0.59%

JP Morgan Asset Management

2.03M

+94.16%

T. Rowe Price Associates, Inc.

Star Investors

1.46M

+3.09%

Renaissance Technologies LLC

Star Investors

2.50M

+0.53%

Citadel Advisors LLC

889.03K

-64.97%

Wellington Management Company, LLP

2.10M

+43.95%

Geode Capital Management, L.L.C.

1.97M

+5.05%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.99, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.21. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.